Pfizer vaccine ruling strengthens makers' immunity to lawsuits

Share this article:
The Supreme Court bolstered a law shielding vaccine makers from injury lawsuits.

Six of the court's justices ruled against a Pennsylvania family seeking to sue Pfizer for their daughter's seizure disorder, which they allege was caused by Wyeth predecessor Lederle Laboratories' diphtheria-tetanus-pertussis vaccine, which was discontinued in 1998. The court found that the National Childhood Vaccine Injury Act of 1986, which was designed to keep pharmas from bailing out of the vaccine market by creating a no-fault system of compensation for vaccine-related injury or death, prohibited such a suit. The parents' initial claims were denied by a Federal adjudicator under the 1986 Act. They then filed suit in Pennsylvania.

Writing for the majority, Justice Antonin Scalia said: “Provided that there was proper manufacture and warning, any remaining side effects, including those resulting from design defects, are deemed to have been unavoidable.”

Justices Sonia Sotomayor and Ruth Bader Ginsburg dissented, while Justice Elena Kagan recused herself.  In her dissent, Sotomayor said the decision ignores the intent of Congress and “leaves a regulatory vacuum in which no one ensures that vaccine manufacturers adequately take account of scientific and technological advancements when designing or distributing their products.”

Pfizer hailed the decision as “a win for public health.” EVP and general counsel Amy Schulman said in a statement: “The Vaccine Act that Congress enacted nearly 25 years ago appropriately places the responsibility for determining the optimal design of life-saving childhood vaccines in the hands of expert federal agencies, not a patchwork of state tort systems.”



 
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.